Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYan‐Jing LiuLCLi ChaiDYDavid T Yeung

Discussion

Loading...

Member takes

Overview

Observational analysis uncovered methylation changes in CMML patients, suggesting DNA methylation influences treatment response.

Key Points

  • Methylation changes were linked to patient responses to treatment in individuals with CMML, revealing potential biomarkers.
  • Patients with more triggered Mesa exhibited superior outcomes, with a mean of 314,000 compared to 141,000 in non-responders.
  • Analysis incorporated methylation profiling and RNA sequencing to gauge epigenetic progression effectively.
  • Findings highlight the importance of methylation changes in defining therapeutic approaches for myeloid malignancies.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4adhttps://doi.org/10.1182/blood-2025-3231
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1DNA methylation instability as a biomarker to predict resistance or progression to advanced disease Phase following tyrosine kinase inhibitor therapy in chronic myeloid leukemia2025
  2. 2Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood2025
  3. 3Assessment of peripheral blood <scp>DNA</scp> methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the <scp>EWOG</scp>‐<scp>MESRAT</scp> study2025
  4. 4Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation2025 · 4 citations
  5. 5Clone-specific epigenetic regulatory mechanisms in ASXL1-mutant chronic myelomonocytic leukemia2025